Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489600 | 0.99 | ALDH1A1 (0.46) | MAPTALDH1A1KDM4ENPC1GAA | |
| SCHEMBL987879 | 0.99 | ALDH1A1 (0.46) | MAPTALDH1A1KDM4ENPC1GAA | |
| SCHEMBL29360781 | 0.99 | ALDH1A1 (0.46) | MAPTALDH1A1KDM4ENPC1GAA | |
| SCHEMBL2892703 | 0.98 | ALDH1A1 (0.48) | MAPTALDH1A1KDM4ENPC1GAA | |
| SCHEMBL2892755 | 0.98 | ALDH1A1 (0.45) | MAPTALDH1A1KDM4ENPC1GAA | |
| Lithium SCHEMBL2893392 | 0.98 | ALDH1A1 (0.45) | MAPTALDH1A1KDM4ENPC1GAA | |
| SCHEMBL2893387 | 0.98 | ALDH1A1 (0.45) | MAPTALDH1A1KDM4ENPC1GAA | |
| Potassium SCHEMBL2892705 | 0.98 | ALDH1A1 (0.45) | MAPTALDH1A1KDM4ENPC1GAA | |
| SCHEMBL2892748 | 0.98 | ALDH1A1 (0.45) | MAPTALDH1A1KDM4ENPC1GAA | |
| Ammonia Solution, Strong SCHEMBL2895237 | 0.98 | ALDH1A1 (0.45) | MAPTALDH1A1KDM4ENPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100285964-A1 | SALTS OF 2-IODO-N-[(4-METHOXY-6-METHYL-1,3, 5-TRIAZINE-2-YL) CARBAMOYL] BENZENESULFONAMIDE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYERCROPSCIENCE AG (DE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285964-A1 | SALTS OF 2-IODO-N-[(4-METHOXY-6-METHYL-1,3, 5-TRIAZINE-2-YL) CARBAMOYL] BENZENESULFONAMIDE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES AND PLANT GROWTH REGULATORS | MYB, INMT, AS3MT | MAPT 4121/4885ALDH1A1 2663/4885KDM4E 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.